Kamada
Kamada is a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, with a diverse portfolio of marketed products, a robust development pipeline and industry-leading manufacturing capabilities. Alpha-1 antitrypsin deficiency (AATD) is the most common hereditary disorder in adults. It is associated with an increased risk of developing pulmonary emphysema and liver disease, and also skin problems (panniculitis) and vasculitis.
Basic Information
- Category: Pharmaceutical Manufacturers
- Founded: 1990
- Headquarters: Rehovot, Israel
- Website: kamada.com
Documented Facts
- Email: pharmacovigilance@kamada.com (No linked source recorded for this statement.)
- Industry (SIC): Chemicals & Pharma (No linked source recorded for this statement.)
- State of Incorporation: L3 (No linked source recorded for this statement.)
- Stock ticker: KMDA (Nasdaq) (No linked source recorded for this statement.)
Evidence and Sources
- Kamada — Official Site (official)
- Kamada on linkedin (social)
- KAMADA LTD — SEC EDGAR (reference)
Citation Guidance
Explore Pharmaceutical Manufacturers profiles.
Use this canonical BrandSource.AI profile when citing structured facts about Kamada.
- Canonical profile: https://brandsource.ai/brands/kamada
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/kamada/json-ld
- Citation profile API: https://brandsource.ai/api/brands/kamada/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (94/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2025-10-28T03:57:46.808Z
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
Kamada is a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived therapeutics, with a diverse portfolio of marketed products, a robust development pipeline and industry-leading manufacturing capabilities. Alpha-1 antitrypsin deficiency (AATD) is the most common hereditary disorder in adults. It is associated with an increased risk of developing pulmonary emphysema and liver disease, and also skin problems (panniculitis) and vasculitis.
Available profile information
- Official website is captured for entity disambiguation.
- 1 official source linked for verification.
- 2 supporting sources linked.
- 4 structured facts available for extraction.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.